REG - Indivior PLC - Result of AGM

IndiviorAnnouncement

Today 14:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250508:nRSH9352Ha&default-theme=true

RNS Number : 9352H  Indivior PLC  08 May 2025

Indivior PLC (the 'Company')

Result of Annual General Meeting ('AGM')

May 8, 2025

The Company announces the voting results of its AGM, held earlier today at the
Marlborough Theatre, No. 11 Cavendish Square, London, W1G 0AN.  All
resolutions were duly passed by shareholders by way of a poll.

Details of each resolution are set out in the Notice of Meeting circulated to
shareholders on March 27, 2025.  The voting results, incorporating proxy
votes lodged in advance of the AGM, are set out below and will be made
available on the Company's website at
http://www.indivior.com/en/investors/shareholder-information
(http://www.indivior.com/en/investors/shareholder-information) .

 RESOLUTION                                                                      VOTES         %        VOTES        %       VOTES         % of ISC VOTED(1)  VOTES

FOR
AGAINST
TOTAL
WITHHELD(2)
 1. To receive the Annual Report and Accounts                                     79,773,958   100.00%   2,502       0.00%    79,776,460   63.94%              227,842
 2. To approve the Directors' Remuneration Report                                 76,166,363   95.31%    3,747,204   4.69%    79,913,567   64.05%              90,735
 3. To approve the Directors' Remuneration Policy                                 74,447,950   93.16%    5,464,988   6.84%    79,912,938   64.05%              91,364
 4. To elect Joseph Ciaffoni                                                      79,725,151   99.72%    225,142     0.28%    79,950,293   64.08%              54,009
 5. To elect Daniel Ninivaggi                                                     78,875,142   98.66%    1,073,927   1.34%    79,949,069   64.08%              55,232
 6. To elect Dr. David Wheadon                                                    65,324,886   81.71%    4,624,894   18.29%   79,949,780   64.08%              54,521
 7. To re-elect Dr. Keith Humphreys                                               71,220,343   89.08%    8,732,129   10.92%   79,952,472   64.08%              51,830
 8. To re-elect Barbara Ryan                                                      66,278,304   82.93%   13,645,584   17.07%   79,923,888   64.06%              80,414
 9. To re-elect Mark Stejbach                                                     66,449,177   83.11%   13,503,305   16.89%   79,952,482   64.08%              51,820
 10. To re-elect Juliet Thompson                                                  65,523,796   81.98%   14,399,386   18.02%   79,923,182   64.06%              81,120
 11. To re-appoint PricewaterhouseCoopers LLP as Auditor                          79,077,334   98.90%    880,211     1.10%    79,957,545   64.08%              46,757
 12. To authorize the Audit & Risk Committee to determine the remuneration        79,820,100   99.83%    138,138     0.17%    79,958,238   64.08%              46,064
 of the Auditor
 13. To authorize the Company and any of its UK subsidiaries to make political    78,832,165   98.79%    964,328     1.21%    79,796,493   63.96%              207,808
 donations and incur political expenditure
 14. To authorize the Directors to allot shares                                   79,153,182   99.09%    723,748     0.91%    79,876,930   64.02%              127,372
 15. To authorize the Directors to disapply pre-emption rights up to 10% of the   78,961,024   98.82%    941,908     1.18%    79,902,932   64.04%              101,370
 issued capital (Special Resolution)
 16. To authorize the Directors to disapply pre-emption rights up to an           78,287,338   98.02%    1,584,404   1.98%    79,871,742   64.02%              132,559
 additional 10% for transactions which the Board determines to be an
 acquisition or other capital investment (Special Resolution)
 17. To authorize market purchases of the Company's ordinary shares (Special      79,831,447   99.94%    48,147      0.06%    79,879,594   64.02%              124,708
 Resolution)
 18. To call a general meeting other than an annual general meeting on not less   78,847,776   98.60%    1,119,509   1.40%    79,967,285   64.09%              37,017
 than 14 clear days' notice (Special Resolution)
 19. To adopt the new Articles of Association (Special Resolution)                79,666,957   99.64%    290,995     0.36%    79,957,952   64.08%              46,350

 

Notes:

 

1.         As at the close of business on May 8, 2024, the total
number of ordinary shares of US$0.50 eligible to be voted at the AGM was
124,769,533.  Therefore, the total voting rights in the Company as at that
time was 124,769,533.

2.         A vote withheld is not a vote in law and is not counted in
the calculation of the votes for or against a resolution.

A copy of the special business resolutions will be submitted to the National
Storage Mechanism and will be available to view at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) in due course.

Computershare Investor Services PLC acted as scrutineer of the poll on all
resolutions.

 

Key Contacts:

Jason Thompson

VP, Investor Relations

+1 804-402-7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

Tim Owens

Director, Investor Relations

+1 804-263-3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

Alice Givens

Company Secretary

+1 804-659-7741 or alice.givens@Indivior.com
(mailto:alice.givens@Indivior.com)

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat opioid use disorder (OUD). Our vision
is that all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of OUD.
Indivior is dedicated to transforming OUD from a global human crisis to a
recognized and treated chronic disease. Building on its global portfolio of
OUD treatments, Indivior has a pipeline of product candidates designed to
expand on its heritage in this category. Headquartered in the United States in
Richmond, VA, Indivior employs over 1,000 individuals globally and its
portfolio of products is available in over 30 countries worldwide.
Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGLVLFBEELEBBD